Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12620001287921
Ethics application status
Approved
Date submitted
17/09/2020
Date registered
27/11/2020
Date last updated
27/11/2020
Date data sharing statement initially provided
27/11/2020
Type of registration
Retrospectively registered
Titles & IDs
Public title
Assessment of DNA damage-repair capacity in systemic lupus erythematosus patients as a potential biomarker of response to cyclophosphamide.
Query!
Scientific title
Assessment of DNA damage-repair capacity in systemic lupus erythematosus patients as a potential biomarker of response to cyclophosphamide.
Query!
Secondary ID [1]
302335
0
none
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Lupus nephritis
319105
0
Query!
Condition category
Condition code
Inflammatory and Immune System
317063
317063
0
0
Query!
Autoimmune diseases
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
False
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
The study involves collection of a single blood sample from patients diagnosed with systemic lupus erythematosus. Information on age, gender, self-identified ethnicity will be collected as well as data from the medical notes about recent lab-test results on lupus, kidney function and medications received as part of routine care.
This is a single observation at this one timepoint.
Query!
Intervention code [1]
318627
0
Early Detection / Screening
Query!
Comparator / control treatment
Healthy volunteers donating blood from 2018- to current date. These are volunteers recruited at the University of Auckland under a separate ethics approval for collection of blood sample for use in this assay
Query!
Control group
Historical
Query!
Outcomes
Primary outcome [1]
325157
0
To assess the range of IC50 values of phosphoramide-induced QPCR-block in ex vivo treated peripheral blood mononuclear cells (PBMC) from lupus nephritis patients.
Query!
Assessment method [1]
325157
0
Query!
Timepoint [1]
325157
0
Following sample collection for each participant
Query!
Secondary outcome [1]
387029
0
none
Query!
Assessment method [1]
387029
0
Query!
Timepoint [1]
387029
0
not applicable
Query!
Eligibility
Key inclusion criteria
>18 years of age
Diagnosed with lupus nephritis
Able to give informed consent
Not currently receiving cyclophosphamide or other alkylating agent
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Not able to provide a blood sample
Currently taking cyclophosphamide or other alkylating agent
Query!
Study design
Purpose
Natural history
Query!
Duration
Cross-sectional
Query!
Selection
Convenience sample
Query!
Timing
Both
Query!
Statistical methods / analysis
The range of IC50 values (in ex vivo treated blood cells) from up to n=17 donors will be reported. The mean and SD (or median, IQR) will be reported. The data will be compared to data collected from a historical group of healthy volunteer donors. Comparison of the means of the continuous variable ( IC50 values) between the groups (patient vs heathy controls) will be assessed using T-test and a P value <0.05 will be considered significant.
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
19/10/2020
Query!
Date of last participant enrolment
Anticipated
20/10/2022
Query!
Actual
Query!
Date of last data collection
Anticipated
20/10/2022
Query!
Actual
Query!
Sample size
Target
17
Query!
Accrual to date
3
Query!
Final
Query!
Recruitment outside Australia
Country [1]
22993
0
New Zealand
Query!
State/province [1]
22993
0
Auckland
Query!
Funding & Sponsors
Funding source category [1]
306764
0
University
Query!
Name [1]
306764
0
University of Auckland
Query!
Address [1]
306764
0
Private Bag 92019. Victoria Street West Auckland 1142. New Zealand
Query!
Country [1]
306764
0
New Zealand
Query!
Primary sponsor type
University
Query!
Name
University of Auckland
Query!
Address
Private Bag 92019. Victoria Street West Auckland 1142. New Zealand
Query!
Country
New Zealand
Query!
Secondary sponsor category [1]
307318
0
None
Query!
Name [1]
307318
0
Query!
Address [1]
307318
0
Query!
Country [1]
307318
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
306929
0
Northern B Health and Disability Ethics Committee
Query!
Ethics committee address [1]
306929
0
Ministry of Health Health and Disability Ethics Committees PO Box 5013 Wellington 6140
Query!
Ethics committee country [1]
306929
0
New Zealand
Query!
Date submitted for ethics approval [1]
306929
0
23/07/2020
Query!
Approval date [1]
306929
0
17/08/2020
Query!
Ethics approval number [1]
306929
0
20/NTB/182
Query!
Summary
Brief summary
Cyclophosphamide is one of several medications that may be used to help to treat damage to the kidney that can occur in some patients with systemic lupus erythematosus (lupus nephritis). Unfortunately treatment with cyclophosphamide is not always successful in every patient. Cyclophosphamide works by killing the over-active immune cells which are causing inflammation in the kidney. Recent international research suggests that, compared with healthy volunteers, immune cells from patients with lupus have a decreased ability to repair the type of damage caused by drugs like cyclophosphamide. We want to investigate whether a test using cells collected from a blood sample can detect this type of decreased repair activity.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
105482
0
A/Prof Nuala Helsby
Query!
Address
105482
0
Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1145, New Zealand.
Query!
Country
105482
0
New Zealand
Query!
Phone
105482
0
+6499239831
Query!
Fax
105482
0
Query!
Email
105482
0
[email protected]
Query!
Contact person for public queries
Name
105483
0
Nuala Helsby
Query!
Address
105483
0
Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.
Query!
Country
105483
0
New Zealand
Query!
Phone
105483
0
+6499239831
Query!
Fax
105483
0
Query!
Email
105483
0
[email protected]
Query!
Contact person for scientific queries
Name
105484
0
Nuala Helsby
Query!
Address
105484
0
Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.
Query!
Country
105484
0
New Zealand
Query!
Phone
105484
0
+6499239831
Query!
Fax
105484
0
Query!
Email
105484
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
This is an ex vivo study of activity in blood cells and only the range of data will be reported.
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF